Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 56.64 USD 2.39% Market Closed
Market Cap: 3.5B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PTGX stock under the Base Case scenario is 15.64 USD. Compared to the current market price of 56.64 USD, Protagonist Therapeutics Inc is Overvalued by 72%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PTGX Relative Value
Base Case
15.64 USD
Overvaluation 72%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

16.9
P/S
P/S
Price to Sales
16.9
vs History
50
vs Industry
51
Median 3Y
8.8
Median 5Y
20.2
Industry
7.5
Forward
42.3
More Details
62.4
P/E
P/E
Price to Earnings
62.4
vs History
0
vs Industry
10
Median 3Y
-3.2
Median 5Y
-7.6
Industry
23.6
Forward
-28.6
More Details
10.4
P/OCF
P/OCF
Price to OCF
10.4
vs History
11
vs Industry
10
Median 3Y
-4.2
Median 5Y
-9.6
Industry
20.2
More Details
10.5
P/FCFE
P/FCFE
Price to FCFE
10.5
vs History
11
vs Industry
9
Median 3Y
-4.2
Median 5Y
-9.5
Industry
22.9
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
20
vs Industry
20
Median 3Y
3.7
Median 5Y
4.1
Industry
2.8
More Details
14.1
EV/S
EV/S
Enterprise Value to Sales
14.1
vs History
49
vs Industry
45
Median 3Y
4.7
Median 5Y
13
Industry
7.7
Forward
35.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
More Details
95.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
95.6
vs History
0
vs Industry
11
Median 3Y
-0.9
Median 5Y
-4.9
Industry
4.9
Forward
-20
More Details
107.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
107.7
vs History
0
vs Industry
10
Median 3Y
-0.9
Median 5Y
-4.9
Industry
4.9
Forward
-22
More Details
8.7
EV/OCF
EV/OCF
Enterprise Value to OCF
8.7
vs History
9
vs Industry
11
Median 3Y
-1.5
Median 5Y
-6.6
Industry
5.4
More Details
8.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8.7
vs History
9
vs Industry
8
Median 3Y
-1.4
Median 5Y
-6.6
Industry
4
More Details
17.8
EV/IC
EV/IC
Enterprise Value to IC
17.8
vs History
63
vs Industry
22
Median 3Y
16.5
Median 5Y
32.3
Industry
5.1
More Details

Multiples Across Competitors

PTGX Competitors Multiples
Protagonist Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
3.5B USD 16.9 62.4 95.6 107.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 182 884.2 -162 466.2 -197 285.8 -195 034.5
US
Abbvie Inc
NYSE:ABBV
336.6B USD 5.9 81 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
160.8B USD 4.7 27.1 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
136.8B USD 4.8 22.9 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD 10.9 -122 26 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 060.9 -525.9 -572.7 -557.4
AU
CSL Ltd
ASX:CSL
120.3B AUD 5.2 28.6 17.6 22
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.3B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -60.9 -65.6 -59.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42.1B USD 17.9 -156 -699.8 -350.7
P/E Multiple
Earnings Growth PEG
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average P/E: 39.2
62.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 466.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.9
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -122 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -525.9 N/A N/A
AU
CSL Ltd
ASX:CSL
28.6
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -156 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBITDA: 27.3
95.6
-37%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 285.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.6
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -699.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBIT: 33
107.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 034.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.4 N/A N/A
AU
CSL Ltd
ASX:CSL
22
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -350.7 N/A N/A

See Also

Summary
PTGX intrinsic value, competitors valuation, and company profile.
DCF Valuation
PTGX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PTGX stock valuation using valuation multiples.
Wall Street Estimates
PTGX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PTGX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 268,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.